Literature DB >> 15905878

Cell size reduction induced by inhibition of the mTOR/S6K-signaling pathway protects Jurkat cells from apoptosis.

C Fumarola1, S La Monica, R R Alfieri, E Borra, G G Guidotti.   

Abstract

In Jurkat cells, the decreased cell growth rate associated with a long-lasting deactivation of the mammalian target of rapamycin (mTOR)/p70 ribosomal S6 kinase (S6K)-signaling pathway generates a cell population of progressively reduced cellular mass and size. When promoted by rapamycin as prototype inhibitor, the mTOR deactivation-dependent cell size reduction was associated with slowed, but not suppressed, proliferation. Small-size cells were significantly protected from apoptosis induced by Fas/Apo-1 death-receptor activation (as shown by reduced procaspase cleavage and decreased catalytic activity of relevant caspases) or by stress signals-dependent mitochondrial perturbation (as shown by reduced cleavage of caspase-2, lower dissipation of mitochondrial membrane potential and decreased release of cytochorome c and apoptosis-inducing factor from mitochondria). Protection faded when reactivation of the mTOR/S6K pathway promoted the cell recovery to normal size. These results suggest that cells induced to reduce their mass by the mTOR deactivation-dependent inhibition of cell growth become more resilient to lethal assaults by curbing the cell's suicidal response.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15905878     DOI: 10.1038/sj.cdd.4401660

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  21 in total

1.  Rapamycin inhibits liver growth during refeeding in rats via control of ribosomal protein translation but not cap-dependent translation initiation.

Authors:  Padmanabhan Anand; Philip A Gruppuso
Journal:  J Nutr       Date:  2006-01       Impact factor: 4.798

2.  Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress.

Authors:  Roberta R Alfieri; Mara A Bonelli; Andrea Cavazzoni; Maurizio Brigotti; Claudia Fumarola; Piero Sestili; Paola Mozzoni; Giuseppe De Palma; Antonio Mutti; Domenica Carnicelli; Federica Vacondio; Claudia Silva; Angelo F Borghetti; Kenneth P Wheeler; Pier Giorgio Petronini
Journal:  J Physiol       Date:  2006-07-27       Impact factor: 5.182

3.  Understanding PLZF: two transcriptional targets, REDD1 and smooth muscle α-actin, define new questions in growth control, senescence, self-renewal and tumor suppression.

Authors:  Marina Kolesnichenko; Peter K Vogt
Journal:  Cell Cycle       Date:  2011-03-01       Impact factor: 4.534

4.  Loss of GSK-3 Causes Abnormal Astrogenesis and Behavior in Mice.

Authors:  Eui-Man Jung; Minhan Ka; Woo-Yang Kim
Journal:  Mol Neurobiol       Date:  2015-07-17       Impact factor: 5.590

5.  Enhanced production and isotope enrichment of recombinant glycoproteins produced in cultured mammalian cells.

Authors:  David Skelton; Abbey Goodyear; Daqun Ni; Wendy J Walton; Myron Rolle; Joan T Hare; Timothy M Logan
Journal:  J Biomol NMR       Date:  2010-08-04       Impact factor: 2.835

6.  Pharmacological retention of oral mucosa progenitor/stem cells.

Authors:  K Izumi; K Inoki; Y Fujimori; C L Marcelo; S E Feinberg
Journal:  J Dent Res       Date:  2009-11-05       Impact factor: 6.116

Review 7.  Molecular mechanisms of mTOR-mediated translational control.

Authors:  Xiaoju Max Ma; John Blenis
Journal:  Nat Rev Mol Cell Biol       Date:  2009-04-02       Impact factor: 94.444

8.  Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion.

Authors:  Silvia La Monica; Roberta Minari; Daniele Cretella; Mara Bonelli; Claudia Fumarola; Andrea Cavazzoni; Maricla Galetti; Graziana Digiacomo; Federica Riccardi; Pier Giorgio Petronini; Marcello Tiseo; Roberta Alfieri
Journal:  Target Oncol       Date:  2019-10       Impact factor: 4.493

9.  Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations.

Authors:  Elio Adib; Katarzyna Klonowska; Krinio Giannikou; Khanh T Do; Solida Pruitt-Thompson; Ketki Bhushan; Matthew I Milstein; Jennifer Hedglin; Katherine E Kargus; Lynette M Sholl; Junko Tsuji; David M Hyman; Anne Sisk; Geoffrey I Shapiro; Hebert A Vargas; James J Harding; Martin H Voss; Gopa Iyer; David J Kwiatkowski
Journal:  Clin Cancer Res       Date:  2021-03-16       Impact factor: 12.531

10.  Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.

Authors:  Kein-Leong Yim
Journal:  Cancer Manag Res       Date:  2012-07-31       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.